Management of Glipizide in Patients with Renal Impairment

Introduction to Glipizide Adjustment

The American Heart Association recommends reducing glipizide to 2.5-5 mg once daily maximum in patients with a GFR of 37 mL/min/1.73 m², and adding an SGLT2 inhibitor immediately for kidney and cardiovascular protection 1, 2, 3

For patients with GFR 30-44 mL/min/1.73 m², the American Diabetes Association suggests initiating glipizide conservatively at 2.5 mg once daily and titrating slowly 3
The maximum dose of glipizide should not exceed 5 mg once daily at this GFR level, as recommended by the American College of Cardiology 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend adding an SGLT2 inhibitor for all patients with type 2 diabetes, chronic kidney disease, and eGFR ≥30 mL/min/1.73 m² due to documented kidney and cardiovascular benefits 5, 4
When adding an SGLT2 inhibitor, the American Diabetes Association recommends reducing the glipizide dose by 50% or discontinuing it entirely to prevent hypoglycemia 4

The American College of Cardiology recommends using metformin safely with eGFR ≥30 mL/min/1.73 m², initiating at half the usual starting dose and titrating to half the maximum recommended dose 1, 5, 2
Metformin can be used with eGFR ≥30 mL/min/1.73 m², as stated by the American Diabetes Association 5, 2

The American Heart Association suggests adding a GLP-1 receptor agonist if glycemic targets are still not met after optimizing metformin and adding an SGLT2 inhibitor, rather than continuing glipizide 5, 4
GLP-1 agonists can be used safely with eGFR >15 mL/min/1.73 m² without dose adjustment, as recommended by the American College of Cardiology 1, 2

The American Diabetes Association recommends transitioning completely off glipizide given the patient's renal function and availability of safer, more effective alternatives 3, 4
All sulfonylureas carry significant hypoglycemia risk in renal impairment, and newer agents are superior for kidney and cardiovascular protection, as stated by the American Heart Association 1, 2, 4

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring kidney function every 3-6 months at this GFR level 5, 3
Intensive glucose monitoring should be implemented, especially during the medication transition, as recommended by the American Diabetes Association 4

The American College of Cardiology recommends never increasing glipizide dose beyond 5 mg daily at this GFR level, even if blood sugar remains elevated 3
Avoid combining glipizide with gemfibrozil, which significantly increases hypoglycemia risk, as stated by the American Heart Association 4

Immediately reduce glipizide to 2.5-5 mg once daily maximum, as recommended by the American Diabetes Association 3
Add SGLT2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin), as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 5
Ensure metformin is optimized (if eGFR ≥30, use half-maximum dose), as recommended by the American College of Cardiology 5, 2
If glycemic targets still not met, add GLP-1 receptor agonist, as recommended by the American Heart Association 5, 4
Plan to discontinue glipizide once other agents are optimized, as recommended by the American Diabetes Association 3, 4
Monitor glucose intensively and kidney function every 3-6 months, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 5, 3, 4